I-124 pre-therapy dosimetry for the treatment of differentiated thyroid cancer: A single center experience

Document Type : Original Article


Nuclear Medicine Department, Institut Kanser Negara, Putrajaya, Malaysia


Introduction:The maximum tolerable activity (MTA) of I-131 in radioiodine therapy is an established surrogate quantity to ensure that the therapeutic activity does not produce severe damages to the bone marrow and lung. The aim of this study was to estimate the MTAs for high-risk patients using I-124 pre-therapy dosimetry and to compare the results with published literature.
Methods: A total of 15 thyroid cancer patients, who received I-124 pre-therapy dosimetry procedure, had underwent serial blood sampling and whole-body external measurements at approximately 1–2, 4, 24, 48, and 96 h or longer after I-124 administration. The blood sampling and whole-body external measurements were used to calculate the MTA for each individual using published dosimetry procedures.
Results: The estimated MTAs ranged from 14 to 34 GBq. The range of blood residence and whole-body residence times were 2.6 h and 22.4 h, respectively; the 48-h whole-body retention value ranged from 2% - 14%. An overall good MTA agreement can be found between our centre and the results of the well-established centre (Essen, Germany) that included 108 patients.

Conclusion: I-124 pre-therapy dosimetry provides toxicity levels similar to published values. Further prospective studies are warranted to assess the benefits of I-124 pre-therapy dosimetry for the individual patient and, in particular, the patient outcome.


Main Subjects

  1. Freudenberg LS, Jentzen W, Görges R, Petrich T, Marlowe RJ, Knust J, Bockisch A. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin. 2007;46(4):121-8.
  2. Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA. Bone marrow dosimetry using 124I-PET. J Nucl Med. 2012 Apr;53(4):615-21.
  3. Jentzen W, Bockisch A, Ruhlmann M. Assessment of simplified blood dose protocols for the estimation of the maximum tolerable activity in thyroid cancer patients undergoing radioiodine therapy using 124I. J Nucl Med. 2015 Jun;56(6):832-8.
  4. Jentzen W, Hoppenbrouwers J, van Leeuwen P, van der Velden D, van de Kolk R, Poeppel TD, Nagarajah J, Brandau W, Bockisch A, Rosenbaum-Krumme S. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging. J Nucl Med. 2014 Nov;55(11):1759-65.
  5. Cascini GL, Niccoli Asabella A, Notaristefano A, Restuccia A, Ferrari C, Rubini D, Altini C, Rubini G.  124 Iodine: a longer-life positron emitter isotope-new opportunities in molecular imaging. Biomed Res Int. 2014;2014:672094.
  6. Wierts R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, Backes WH, Mottaghy FM, Jentzen W. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT. J Nucl Med. 2016 Jul;57(7):1027-32.
  7. Jentzen W, Verschure F, van Zon A, van de Kolk R, Wierts R, Schmitz J, Bockisch A, Binse I. Response assessment of bone metastases from differentiated thyroid cancer patients in the initial radioiodine treatment using iodine-124 PET imaging. J Nucl Med. May 19, 2016.
  8. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962 Jan;87:171-82.
  9. Benua RS, Leeper RD. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. In: Medeiros-Neto G, Gaitan E. Frontiers in Thyroidology. New York, NY: Plenum Medical Book Co; 1986. p. 1317–21.
  10. Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M; EANM Dosimetry Committee. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008 Jul;35(7):1405-12.
  11. Beattie BJ, Pentlow KS, O'Donoghue J, Humm JL. Humm. A recommendation for revised dose calibrator measurement procedures for 89Zr and 124I. PLoS One. 2014 Sep 9;9(9):e106868.
  12. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol. 1995 Apr;89(4):748-56.
  13. Piruzan E, Haghighatafshar M, Faghihi R, Entezarmahdi SM. Calculation of Blood Dose in Patients Treated With 131I Using MIRD, Imaging, and Blood Sampling Methods. Medicine (Baltimore). 2016 Mar;95(11):e3154.
  14. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, Robertson JS, Howell RW, Wessels BW, Fisher DR, Weber DA, Brill AB. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999 Feb;40(2):37S-61S.
  15. Lee JJ, Chung JK, Kim SE, Kang WJ, Park DJ, Lee DS, Cho BY, Lee MC. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med. 2008 Nov;22(9):727-34.
  16. Pettinato C, Spezi E, Nanni C, Grassetto G, Monari F, Allegri V, Civollani S, Cima S, Zagni P, Mazzarotto R, Colletti PM, Rubello D, Fanti S. Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning. Clin Nucl Med. 2014 Aug;39(8):e367-74.